Digital Content 
NEWS #PharmaBuzz
05 Dec 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/12/05/3200660/0/en/UroGen-Pharma-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html
06 Nov 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/11/06/3182531/0/en/UroGen-Reports-Third-Quarter-2025-Financial-Results-as-ZUSDURI-Launch-Gains-Momentum.html
28 Jul 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/07/28/3122406/0/en/UroGen-Announces-Publication-of-Phase-3b-Study-Results-Demonstrating-the-Feasibility-of-Home-Instillation-of-ZUSDURI-for-Recurrent-Low-Grade-Intermediate-Risk-Non-Muscle-Invasive-B.html
21 Jul 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/07/21/3118671/0/en/UroGen-Announces-Five-Year-Long-Term-Extension-Study-of-the-OPTIMA-II-Trial-Demonstrates-Long-Term-Durability-of-Response-to-ZUSDURI-in-Patients-with-Low-Grade-Intermediate-Risk-No.html
14 Jun 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250610841284/en/U.S.-FDA-Approves-UroGens-ZUSDURI-mitomycin-for-Intravesical-Solution-as-the-First-and-Only-Medication-for-Recurrent-Low-Grade-Intermediate-Risk-Non-Muscle-Invasive-Bladder-Cancer-LG-IR-NMIBC
06 Jun 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250606792691/en/UroGen-Pharma-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635c4
Share 